Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TMC Life Sciences BhdXKLS:0101 60 EV-to-EBIT is 27.63 as of Aug. 05, 2026, which is 13% below its 10-year median of 31.71. GuruFocus rates XKLS:0101 with a GF Score™ of 60/100 and a GF Value™ of RM0.63 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 470 Healthcare Providers & Services companies, TMC Life Sciences Bhd ranks worse than 74.04% on this metric.
The historical rank and industry rank for TMC Life Sciences Bhd's EV-to-EBIT or its related term are showing as below:
XKLS:0101'
s EV-to-EBIT Range Over the Past 10 Years
Min: 14.97 Med: 31.71 Max: 115.96
Current: 27.63
During the past 13 years, the highest EV-to-EBIT of TMC Life Sciences Bhd was 115.96. The lowest was 14.97. And the median was 31.71.
XKLS:0101's EV-to-EBIT is ranked worse than 74.04% of 470
companies
in the Healthcare Providers & Services industry
Industry Median: 15.985
vs XKLS:0101: 27.63
TMC Life Sciences Bhd (XKLS:0101) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
TMC Life Sciences Bhd's Enterprise Value for the quarter that ended in Mar. 2026 was RM874.1 Mil.
TMC Life Sciences Bhd's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was RM29.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, TMC Life Sciences Bhd's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TMC Life Sciences Bhd EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, TMC Life Sciences Bhd's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where TMC Life Sciences Bhd's EV-to-EBIT falls into.
TMC Life Sciences Bhd's current Enterprise Value is RM821.9 Mil.
TMC Life Sciences Bhd's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was RM29.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TMC Life Sciences Bhd (XKLS:0101) has a EV-to-EBIT of 27.63 as of Aug. 05, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on TMC Life Sciences Bhd and its competitors. This is 13% below median its historical median of 31.71. Over the past decade, TMC Life Sciences Bhd's EV-to-EBIT has ranged from 14.97 to 115.96. According to the industry distribution chart, TMC Life Sciences Bhd ranks #348 out of 470 companies in the Healthcare Providers & Services industry, placing it in the top 74%.
Is TMC Life Sciences Bhd's EV-to-EBIT too high?
TMC Life Sciences Bhd's current EV-to-EBIT of 27.63 is 13% below median its 10-year median of 31.71. Over the past 10 years, this metric has ranged from a low of 14.97 to a high of 115.96. The Healthcare Providers & Services industry median EV-to-EBIT is 15.99. TMC Life Sciences Bhd's value of 27.63 is 72.8% above this industry median. Based on the distribution chart, TMC Life Sciences Bhd ranks #348 out of 470 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, TMC Life Sciences Bhd has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TMC Life Sciences Bhd's EV-to-EBIT compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, TMC Life Sciences Bhd ranks #348 out of 470 companies for EV-to-EBIT. This places TMC Life Sciences Bhd in the lower half of its industry. The industry median EV-to-EBIT is 15.99. TMC Life Sciences Bhd's value of 27.63 is 72.8% above this benchmark. Historically, TMC Life Sciences Bhd's own EV-to-EBIT has ranged from 14.97 to 115.96 over the past decade. While the company's 10-year median is 31.71 vs. the industry median of 15.99, TMC Life Sciences Bhd has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.99, based on 470 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TMC Life Sciences Bhd's current EV-to-EBIT of 27.63 is 72.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on TMC Life Sciences Bhd and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TMC Life Sciences Bhd's current EV-to-EBIT is 27.63, which is 13% below median its own 10-year median of 31.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TMC Life Sciences Bhd stock overvalued right now?
Based on GuruFocus' analysis, TMC Life Sciences Bhd (XKLS:0101) is currently considered Modestly Undervalued. The stock's GF Value™ is RM0.63, compared to a current price of RM0.45 — trading 28.6% below its estimated fair value. The current EV-to-EBIT is 27.63, which is 13% below median its 10-year median of 31.71 and 72.8% above the Healthcare Providers & Services industry median of 15.99. TMC Life Sciences Bhd's overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For TMC Life Sciences Bhd (XKLS:0101), the current EV-to-EBIT is 27.63 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TMC Life Sciences Bhd (XKLS:0101) Overvalued in 2026?
Based on GuruFocus' analysis, TMC Life Sciences Bhd stock appears to be undervalued.
The current stock price of RM0.45 is trading 28.6% below its estimated GF Value™ of RM0.63.
GuruFocus considers TMC Life Sciences Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:0101:
EV-to-EBIT: 27.63 (13% below median its 10-year median of 31.71)
GF Value™: RM0.63 vs. price of RM0.45 (28.6% below fair value)
Industry Position: 72.8% above the Healthcare Providers & Services median (#348 of 470)
No single metric tells the full story. See the XKLS:0101 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TMC Life Sciences Bhd is an investment holding company operating a multi-disciplinary tertiary care center and fertility center in Malaysia. It operates Tropicana Medical Centre, Kota Damansara (TMCKD), a medical center located in Petaling Jaya. Its TMCKD provides healthcare services in various medical/surgical specialties and subspecialties, including anesthesiology, cancer, cardiology, colorectal, dermatology, ENT, fertility, gastroenterology, as well as offers internal medicines and respiratory medicines. Its fertility center provides a range of fertility treatments for couples. The company also operates a women's clinic; provides fertility consultancy, laboratory, and embryology services; and offers pharmacy services and products.
60GF Score
Get the complete analysis for XKLS:0101
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0101 has been successfully added to your 
